Madrigal Pharmaceuticals : 1Q25 MDGL Earnings Slides

Published: 2025-05-01 09:18:50 ET MDGL

Published on 05/01/2025 at 09:18

May 1, 2025

NASDAQ: MDGL

© 2025 Madrigal Pharmaceuticals, Inc. All rights reserved.

1Q25 Earnings Call Agenda

Rezdiffra Launch Update

2-Year F4c Data Recap1

F4c late breaker on May 10

Strategy to Expand Our Leadership Position in MASH

1. Two-year data from the active-treatment open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial; additional data will be presented at the European Association for the Study of the Liver (EASL) Congress 2025.

3

Net Sales: Continuing to Generate Strong Uptake

First 12 Months of Net Sales: $317.4M

QoQ growth from 4Q24 to 1Q25

$137.3M

$103.3M

$62.2M

$14.6M

1Q25 net sales

2Q24 3Q24 4Q24 1Q25

Rezdiffra launch is tracking in line with other best-in-class specialty blockbuster launches

Patients on Rezdiffra:

Steadily Adding New Patients

Rezdiffra Potential: 315K Patients Today with Potential for Significant Expansion with Competition

>17,000

>11,800

>6,800

>2,000

Awareness Screening Diagnosis Treatment

High GLP-1 discontinuation rates1

Competitive entrant target market2

2Q24 3Q24 4Q24 1Q25

315K

~5%

Current Rezdiffra F2/F3 target market3

Patients on Rezdiffra as of 1Q25

1. Novo Nordisk: Investor presentation, 1H24, "Patient persistency on anti-obesity medications after 12 months," slide 60 states that approximately 70 percent of patients on semaglutide discontinue after 12 months; 2. Novo Nordisk Capital Markets Day presentation 2024, "~22 million people are expected to live with MASH F2-F4c by 2030," slide 16; 3. An estimated 315,000 patients in the U.S. are diagnosed with moderate to advanced fibrosis (F2/F3) and seen by ~14K target specialists.

Disclaimer

Madrigal Pharmaceuticals Inc. published this content on May 01, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 01, 2025 at 13:14 UTC.